Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 00:25 | 2026-05-07 | PTGX | Protagonist Therapeutics, Inc | Giraudo Bryan | Director | Pharmaceutical Preparations | OPT+S | $100.10 | 59,130 | $5,918,878 | 12,695 | -82.3% |
| 2024-06-21 03:21 | 2024-06-18 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | BUY | $0.59 | 100,000 | $59,110 | 480,010 | +26.3% |
| 2024-03-29 01:05 | 2024-03-27 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | SALE | $1.16 | 6,430 | $7,431 | 92,737 | -6.5% |
| 2023-11-15 02:24 | 2023-11-13 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | BUY | $0.56 | 200,000 | $112,880 | 380,010 | +111.1% |
| 2023-04-05 23:26 | 2023-04-04 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | BUY | $1.02 | 55,000 | $56,095 | 125,990 | +77.5% |
| 2023-03-23 00:17 | 2023-03-20 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | BUY | $0.97 | 50,000 | $48,435 | 70,990 | +238.2% |
| 2022-07-15 23:23 | 2022-07-15 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | BUY | $7.21 | 13,869 | $99,995 | 20,990 | +194.8% |
| 2022-03-24 23:53 | 2022-03-23 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; COO/CFO | Pharmaceutical Preparations | SALE | $8.92 | 10,722 | $95,587 | 99,167 | -9.8% |
| 2021-03-25 23:11 | 2021-03-23 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $9.48 | 5,490 | $52,046 | 109,889 | -4.8% |
| 2020-10-15 02:27 | 2020-10-14 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $10.01 | 3,000 | $30,036 | 7,121 | +72.8% |
| 2020-06-24 00:01 | 2020-06-23 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $12.96 | 2,000 | $25,922 | 4,121 | +94.3% |
| 2019-12-04 02:46 | 2019-12-03 | PTGX | Protagonist Therapeutics, Inc | Giraudo Bryan | Director | Pharmaceutical Preparations | BUY | $5.70 | 8,000 | $45,620 | 8,000 | +100.0% |
| 2019-09-26 23:08 | 2019-09-26 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $16.78 | 1,121 | $18,810 | 2,121 | +112.1% |
| 2019-06-03 23:03 | 2019-05-30 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $18.70 | 1,000 | $18,700 | 1,000 | +100.0% |
| 2019-02-13 01:33 | 2019-02-12 | GOSS | Gossamer Bio, Inc. | Giraudo Bryan | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $16.00 | 6,000 | $96,000 | 23,879 | +33.6% |
| 2018-05-18 00:48 | 2017-05-16 | PTGX | Protagonist Therapeutics, Inc | Giraudo Bryan | Director | Pharmaceutical Preparations | BUY | $6.46 | 10,000 | $64,566 | 10,000 | +100.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.